FDA Approves First US Treatment for the Peripheral Thyroid Effects of MCT8 Deficiency

Good morning, HealthTech insiders. A rare genetic disease has its first FDA-approved treatment in the United States. A routine ECG may now flag some older patients for a closer look at a leaking heart valve. And a cell therapy built to recognize two tumor markers has begun its first clinical test in kidney cancer.

The three developments sit at very different stages. Emcitate has clinical evidence and an approved, specific use. Tempus's ECG-MR has a cleared screening role but still needs a path from flagged ECG to useful care. Link Cell's LNK001 has just reached patients, where the first question is safety. This issue follows the evidence behind each milestone and what would have to happen next.

In today's Signal:

• Emcitate for MCT8 deficiency: FDA approval on September 28 covers peripheral thyrotoxicosis in adults and children. The evidence shows improvements in excess thyroid hormone and related cardiovascular and metabolic measures; the approval does not establish reversal of the disorder's severe neurological impairment.

• Tempus ECG-MR: The company announced 510(k) clearance for AI software that reads 12-lead ECGs from eligible patients aged 65 and older and flags possible moderate or severe mitral regurgitation for further evaluation. A binary flag is not a valve diagnosis.

• Link Cell LNK001: Clinical dosing has begun in a Phase 1 study of dual-antigen, logic-gated CAR-T for advanced clear cell renal cell carcinoma. Its Series A has grown by $30 million to $90 million in total; efficacy has not yet been demonstrated.

• What we're watching next: US access and monitoring for Emcitate, prospective evidence and follow-up imaging after ECG-MR flags, and safety plus early tumor response in LNK001's dose-escalation study.

In partnership with

Elon's new company is private. These 3 tickers aren't.

The next Apple may already exist. Insider sources say Elon has spent two years building a secret device inside Tesla's facilities, one he claims will be "10x bigger than the largest product in history."

There's just one problem: the company is private, and unless you know Elon personally, you can't buy a single share. That was true until Guardian's research team found three public ticker symbols sitting in the launch supply chain.

Click here to see all 3 tickers, free of charge.

You won't hear these names on CNBC, Wall Street hasn't published a word on the connection. But when the launch hits September 21, that quiet ends.

Some are already calling this the biggest opportunity since AI. For anyone who missed Apple before the iPhone, this may be a second look at that kind of setup.

Get the 3 ticker symbols here.

Unlock the free briefing now.

REGULATORY WATCH
1. FDA Approves First US Treatment for the Peripheral Thyroid Effects of MCT8 Deficiency

The FDA approved Emcitate (tiratricol) on September 28 for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome. The inherited transporter defect leaves the brain short of thyroid hormone while excess active hormone circulates in the body. Tiratricol can enter cells without relying on that transporter and lowers excess circulating thyroid hormone.

The details:

• The FDA cites a randomized, placebo-controlled study and a longer-term open-label study. Across them, patients had lower excess thyroid hormone levels and improvements in measures such as heart rate and systolic blood pressure. The release does not claim restored neurological development.

• The once-daily medicine is prepared as a liquid suspension and can be given orally or through a feeding tube. Common adverse reactions reported by FDA include diarrhea, vomiting, rash, and excessive sweating.

• Egetis expects US commercial availability eight to ten weeks after approval and has set up a patient support program with PANTHERx Rare. That is a company forecast, not confirmation of availability or reimbursement. The FDA also granted a rare pediatric disease priority review voucher.

The Signal: The treatment addresses a measurable and damaging part of a complex disease. Its real-world test is whether specialist diagnosis, feeding-tube administration, monitoring, and coverage can get it to the small population that needs it.

REGULATORY WATCH
2. Tempus Gets FDA Clearance to Flag Possible Mitral Regurgitation from a Standard ECG

Tempus announced 510(k) clearance on September 28 for ECG-MR, software that analyzes resting 12-lead ECGs and returns a binary signal associated with possible undiagnosed moderate or severe mitral regurgitation. It is intended for clinical ECGs from patients 65 or older who are at risk of cardiovascular disease, without prior mitral valve intervention or a prior diagnosis of moderate or severe MR.

The details:

• Mitral regurgitation is usually assessed with imaging such as echocardiography. ECG-MR can point clinicians toward further evaluation; it does not measure the leaking valve or establish a diagnosis.

• The product is not for serial monitoring or paced ECGs. Tempus says results should be read alongside the original ECG, symptoms, history, and other tests.

• The announcement provides no sensitivity, specificity, rollout date, site count, or prospective evidence that its alerts improve outcomes. Those are important adoption questions, rather than facts to infer from 510(k) clearance.

The Signal: A test already embedded in care could become a way to find patients who need imaging. The value depends on the entire pathway: who gets flagged, how quickly imaging follows, and whether the diagnosis changes treatment.

ONCOLOGY
3. Link Cell Starts a Dual-Antigen CAR-T Trial in Kidney Cancer and Expands Its Series A

Link Cell Therapies said on September 28 that dosing has begun at MD Anderson for LNK001, a Phase 1 CAR-T candidate in advanced or metastatic clear cell renal cell carcinoma. It is designed to activate when tumor cells co-express CAIX and ENPP3. The company also added $30 million to a previously announced $60 million Series A, taking the round to $90 million.

The details:

• CAIX is found on many clear cell renal tumors, but also on some healthy tissue. The two-marker design aims to reduce unwanted activity in normal tissue. That selectivity is a design hypothesis awaiting human evidence.

• MD Anderson describes two study parts: dose escalation to find a recommended dose, then dose expansion to assess disease control. The study is Phase 1 and enrolling; no response or safety outcomes were reported in the announcement.

• Link says the extra financing will also support a planned colorectal cancer program, with a first-in-human trial intended for 2027. That program remains a plan.

The Signal: The capital and first dose move a proposed targeting solution into a clinical test. The first meaningful readout will be whether the gate behaves as intended in patients, followed by evidence of durable activity.

👀 WHAT WE'RE WATCHING NEXT

• Rare-disease access: When Emcitate reaches US specialty distribution, which patients are diagnosed and covered, and how will clinicians track thyroid and cardiovascular measures over time?

• AI referral quality: What proportion of ECG-MR alerts leads to confirmatory echocardiography, and how many newly identified patients have care that changes as a result?

• Solid-tumor CAR-T safety: Does LNK001 show the intended dual-antigen selectivity in dose escalation, and what early evidence of tumor control follows?

💰 FOLLOW THE MONEY

The deals:

• Link Cell Therapies: A $30 million extension increases its Series A from $60 million to $90 million. The money supports LNK001 and additional logic-gated programs. This is an expansion of one round, not a separate $90 million raise.

• Sofinnova Partners: The firm announced an €82 million final close for MD Start IV, aiming to create six to eight medtech companies over five years. It is capital committed to a fund, not revenue or financing already received by those future companies.

The pattern: Money is being committed at opposite ends of the innovation path: a first-in-human cell therapy and the creation of new medtech companies. Clinical evidence and eventual adoption still determine which bets become useful care.

📆 UPCOMING HEALTHTECH EVENTS

• TCT 2026: October 31-November 3, San Diego: interventional cardiology evidence and practice.

• HLTH USA 2026: November 15-18, The Venetian Expo, Las Vegas: health systems, payers, technology, policy, and investment.

• RSNA 2026: November 29-December 3, McCormick Place, Chicago: radiology research and technology.

🛠️ Trending HealthTech AI Tools

• Tempus ECG-MR: finding a reason to order an echo. The newly cleared software flags ECGs from a defined population aged 65 and older for possible undiagnosed moderate or severe mitral regurgitation. It produces a binary aid, not a diagnosis. Its practical metric is confirmed cases and appropriate follow-up after an alert, as covered in today's lead story.

• CapsoVision AI Highlights: narrowing the capsule-video review. CapsoVision announced on September 28 that FDA clearance had been granted September 25 for its tool to mark suspected lesions in CapsoCam Plus small-bowel studies performed for suspected bleeding. It prioritizes images for a trained reader; it does not replace the physician's interpretation. Watch measured review time and missed-lesion performance in practice.

• Physitrack EMR: the therapy visit becomes the record. Physitrack opened US early access on September 28 for small physical therapy practices. Its AI drafts visit notes and suggests home exercises for clinician approval. Physitrack says its security audit is still underway and it cannot yet sign a Business Associate Agreement for protected health information, so early access should not be read as clearance for live patient records.

🛠️ Trending HealthTech AI Startups

• Basalt Health: post-acute admissions. The Nashville startup announced a $20 million Series A on September 24 to expand software that reads referrals and checks them against facility criteria. At Lifepoint Health, Basalt reports that median chart-processing time fell from 8.5 to 1.2 minutes; that is a company-reported workflow measure, not evidence yet of fewer readmissions. The test now is whether faster processing reliably gets patients to suitable care.

• Ferry Health: care navigation that makes the calls. Ferry emerged from stealth on September 16 with $9 million in seed funding. Its assistant searches for in-network providers, calls to confirm details and availability, and books appointments. The company says more than one million patients have access through partners; access is not the same as completed bookings or faster treatment. Watch appointment completion and how often staff must correct the agent.

• Health Force: agents behind the hospital desk. The Barcelona company raised €4.2 million in seed funding on September 17 for AI agents handling insurance and administrative processes in European hospitals. Its investor says the platform supports work behind more than 200,000 patient cases annually; the open question is how those claims translate into audited accuracy, turnaround time, and staff oversight at more sites.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

• The MCT8 Treatment Boundary: What Emcitate's Approval Changes and What It Leaves Open: mechanism, clinical endpoints, daily delivery, and US access.

• The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value: cleared population, binary alert, confirmatory imaging, and implementation metrics.

• The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis: AND-gate logic, trial design, financing, and the evidence that would change the thesis..

That's it for today!

Today’s headlines mark three different beginnings: a treatment patients can now be prescribed, an AI alert clinicians can act on, and a cell therapy entering its first human trial. The questions ahead are more practical. Will families be able to access Emcitate? Will ECG-MR alerts lead to confirmed diagnoses and useful care? Will LNK001 prove safe as the trial progresses?

Those answers will tell us more than the milestones alone. We’ll keep following the evidence. See you in the next Signal.

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.